007-00 INSIGNIA-PAH - A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of MK-5475 in Adults with Pulmonary Arterial Hypertension

NCT04732221

INSIGNIA-PAH - A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of MK-5475 in Adults with Pulmonary Arterial Hypertension

Associated Conditions

Pulmonary Arterial Hypertension

Principal Investigator

Sponsor

Merck Sharp and Dohme Corp

This trial is testing MK-5475 in people with pulmonary arterial hypertension (PAH). MK-5475 is still being researched. It has not been approved for use to treat PAH. This trial will compare MK-5475 to a placebo. A placebo looks like a trial drug, but it has no active ingredients

This study is currently enrolling.